Protective effects of silymarin against bisphenol A-induced hepatotoxicity in mouse liver

MIHAELA ZAULET1*, STELIANA ELVIRA MARIA KEVORKIAN2*, SORINA DINESCU1*, CORALIA COTORACI3*, MARIA SUCIU2, HILDEGARD HERMAN2, LAURA BUBURUZAN4, LILIANA BADULESCU5, AUREL ARDELEAN4 and ANCA HERMENEAN2,6

1Department of Biochemistry and Molecular Biology, University of Bucharest, 050095 Bucharest; 2Department of Experimental and Applied Biology, Institute of Life Sciences; 3Department of Hematology, Faculty of Medicine, Pharmacy and Dentistry; 4Department of Cell Biology, Faculty of Medicine, ‘Vasile Goldiș’ Western University of Arad, 310414 Arad; 5Department of Bioengineering of Horti-Viticultural System, University of Agronomical Science and Veterinary Medicine, 011464 Bucharest; 6Department of Histology, Faculty of Medicine, ‘Vasile Goldiș’ Western University of Arad, 310414 Arad, Romania

Received November 8, 2015; Accepted June 23, 2016

DOI: 10.3892/etm.2017.4066

Abstract. Bisphenol A (BPA) is an endocrine-disrupting chemical released into the environment, with severe consequences for human health, including metabolic syndrome and associated pathological conditions. Due to limited information on BPA-induced hepatotoxicity, the present study focused on investigating the association between BPA-induced toxicity and inflammatory markers in the liver, and how these injuries may be alleviated using the natural agent silymarin, a flavonoid with antioxidant properties obtained from Silybum marianum. Administration of BPA to male CD-1 mice for 10 days caused a significant increase in the number of cells immunopositive for interleukin 6 and tumor necrosis factor-α, pro-inflammatory cytokines that mediate the hepatic inflammatory response. Treatment with 200 mg/kg of silymarin concurrently with BPA for 10 days resulted in a diminished level of pro-inflammatory cytokines and in significantly reduced ultrastructural injuries. Additionally, silymarin was able to restore the significantly decreased glycogen deposits observed following BPA exposure to normal levels, thus favoring hepatic glycogenesis. This study represents the first report of silymarin ability to reduce structural injuries induced by BPA and to lower the levels of pro-inflammatory cytokines observed in murine liver tissue following exposure to BPA.

Introduction

The liver is involved in the major biochemical and signaling pathways associated with homeostasis (1) and plays a crucial role in interacting with and fighting against xenobiotics. Among these, bisphenol A (BPA) is a fairly ubiquitous compound with certain risks to human health, which have aroused public concern.

In the liver, BPA is metabolized and eliminated essentially as a monoglucuronide (the major metabolite) and/or as a sulfate conjugate. However in Fischer-344 rat hepatocytes, BPA is converted primarily to a diconjugate (glucuronide/sulfate) (2). The hepatic capacity for BPA glucuronidation is predicted to be greater in humans than in rats and mice (2).

Structurally, BPA imitates estrogen and causes dysfunction of the reproductive organs (3,4), having a potential role in severe pathologies such as breast cancer (5). Additionally, exposure to BPA has been associated with various diseases, including cardiovascular disease (6), type II diabetes, altered insulin homeostasis, abnormal liver function (6) and cancer (7).

In particular, the detrimental interaction of BPA with genes associated with adipose tissue and obesity has been linked with metabolic syndrome and associated pathological conditions (8,9). In this context, low-grade chronic inflammation has been identified as a key pathogenic connection between metabolic syndrome, obesity and insulin resistance (10,11). Interleukin (IL)-6 and tumor necrosis factor (TNF)-α are considered pro-inflammatory markers, useful for the identification of low-grade inflammation associated with visceral adiposity (11). Additionally, concerns regarding the presence of BPA in food and the environment have been constantly rising since the dose-dependent incidence of hepatic tumors following perinatal exposure to BPA was reported in isogenic
were performed in compliance with the appropriate laws and conditions as those used for the primary antibodies. Stained sections were analyzed by light microscopy using an Olympus BX43 System Microscope (Olympus, Hamburg, Germany) and photographic images were captured using a digital camera (Olympus XC30).

**Immunohistochemistry.** Paraffin-embedded liver tissue sections of 5-µm thickness were deparaffinized and rehydrated in decreasing concentrations of ethyl alcohol. Rabbit polyclonal anti-TNF-α and anti-IL-6 antibodies (1:100 dilution) were used as primary antibodies. Immunoreactions were visualized employing a Novocastra immunohistochemistry kit with peroxidase and diaminobenzidine chromogen according to the manufacturer's instructions. Negative control slides were processed by the substitution of primary antibodies with irrelevant immunoglobulins of matched isotype, under the same conditions as those used for the primary antibodies. Stained sections were analyzed by light microscopy (Olympus BX43).

**Gene expression analysis by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).** Liver samples were collected from the mice and total RNA was isolated using an RNeasy Mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's protocol. Extracted RNA was tested for integrity using a 2100 BioAnalyzer instrument (Agilent Technologies GmbH, Waldbronn, Germany) and purity using a NanoDrop spectrophotometer (Thermo Scientific, Inc., Waltham, CA, USA). RT-qPCR was performed on a Rotor-Gene thermocycler using a Rotor-Gene SYBR Green RT-PCR Kit (Qiagen GMBH, Hilden, Germany) and the following thermal cycling conditions: 3 min at 95°C, followed by 40 cycles of 30 sec at 95°C, 30 sec at 62°C 45 sec at 72°C, 60 sec at 95°C, 10 sec at 55°C and cooling to 20°C. The sequences of the primers used for TNF-α and IL-6 mRNA detection are presented in Table I. mRNA levels of target genes were normalized to the levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which was used as reference gene and was assessed under the same experimental conditions. Additionally, transcript levels of the target

**Materials and methods**

**Chemicals.** Bisphenol A 99%, silymarin 98% and carboxymethyl cellulose were purchased from Sigma-Aldrich Chemie GmbH (Munich, Germany). TNF-α (sc-52746) and IL-6 (sc-1265-R) antibodies were supplied by Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). A Novoceastra kit for immunohistochemistry (Novolink Max Polymer Detection System; RE7280-K) was purchased from Leica Microsystems GmbH (Wetzlar, Germany).

**Animals.** Male CD-1 mice (n=40; age, 8-10 weeks; body weight, 25±3 g) from a breeding colony at the Animal Facility at 'Vasile Goldiș' Western University of Arad (Arad, Romania) were fed a standard rodent diet and maintained under a 12 h light/dark cycle, with a constant temperature (20±1°C) and humidity (50±5%). All experimental procedures were performed in compliance with the appropriate laws and institutional guidelines, and were approved by the Institutional Ethics Committee of Vasile Goldiș Western University of Arad (Arad, Romania).

**Experimental design.** For analyzing the effect of silymarin on BPA-induced hepatotoxicity, mice were randomly divided into four groups (n=10): Control, BPA, bisphenol A+silymarin (BPA+SY) and silymarin (SY) groups. Silymarin powder was dissolved in 0.7% carboxymethyl cellulose and BPA in 5% ethanol, diluted with corn oil. Vehicles were administered by gavage daily for 10 days to mice in the control group. A dose of 200 mg/kg BPA (31) was administered daily by gavage to mice in the BPA and BPA+SY groups, between days 1 and 10. Silymarin was administered daily for 10 days, at a dose of 200 mg/kg, to mice in the BPA+SY and SY groups.

All mice were sacrificed on day 11 of the experiment. The mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) administered intraperitoneally and sacrificed by cervical dislocation. Liver samples were collected and preserved in a buffered formalin solution for histology and immunohistochemistry or in glutaraldehyde solution for electron microscopy examination.

**Histopathology.** Liver specimens were fixed in 4% phosphate-buffered formalin, embedded in paraffin and cut into 4-µm sections. Sections for histopathological examination were stained with hematoxylin and eosin, and analyzed by light microscopy using an Olympus BX43 System Microscope (Olympus, Hamburg, Germany) and photographic images were captured using a digital camera (Olympus XC30).

Notably, it has previously been shown that BPA has the ability to dysregulate cytokines (13), induce cellular apoptosis in hepatocytes (14) and produce oxidative stress in liver tissue (15,16).

Natural compounds extracted from plants have often been found to have efficient protective and preventive effects against pathological conditions. A flavonoid with important antioxidant properties isolated from the milk thistle *Silybum marianum* seeds is silymarin. Apart from its anti-inflammatory effect (17), silymarin has been shown to protect against hepatotoxicity induced by numerous different agents: Excess iron (18), manganese (19), ethanol (20), carbon tetrachloride (21,22), acetaminophen (paracetamol) (23) and anticancer agents as cisplatin (24), epirubicin (25) and doxorubicin (26). The hepatoprotective and antioxidant activity of silymarin has been attributed to its capacity to eliminate free radicals produced during the hepatic metabolism of toxic substances through the inhibition of the cyclooxygenase cycle and leukotrienes (27). Moreover, this flavonoid has a phenolic structure, which allows electron donation to free radicals and reactive oxygen species (ROS) in order to stabilize them and prevents lipid peroxidation by interaction with intracellular glutathione (27,28). Additionally, silymarin has previously been reported to have anti-proliferative, anti-fibrotic, anti-apoptotic, antiviral and immunomodulatory properties (25,29) and has been shown to inhibit TNF-α expression (30).

The present study aimed to quantify the pro-inflammatory effects of BPA on mouse liver tissue and to propose a potential counteracting agent against the hepatotoxic and inflammatory stress exerted by BPA, namely silymarin. To the best of our knowledge, this is the first study investigating i) the connection between BPA-induced toxicity and low-grade chronic inflammatory markers in the liver and ii) the potential beneficial effect of silymarin in protecting against BPA-induced liver damage.
The administration of BPA caused a significant increase in the number of parenchymal cells immunopositive for IL-6 and TNF-α (Figs. 2B and 3B). No apparent IL-6 or TNF-α expression was detected in non-parenchymal cells. In the BPA+SY group, silymarin treatment decreased the number of cells labeled with both antibodies, compared with the BPA group (Figs. 2C and 3C). No immunopositivity for the group treated with SY alone was detected (Figs. 2D and 3D).

These findings were confirmed by the results of IL-6 and TNF-α RT-qPCR analysis (Figs. 2E and 3E). Evaluation by qPCR demonstrated that exposure to BPA induced high transcript levels of IL-6 in mouse liver tissue (a 1.6-fold increase compared with the control), thus confirming that BPA exerts a hepatotoxic and pro-inflammatory effect (Fig. 2E). Treatment with the natural compound silymarin resulted in very low levels of IL-6 mRNA, comparable with the control. Notably, a statistically significant lower level of IL-6 transcript (P<0.01) was found in livers isolated from mice exposed to a 1:1 ratio of BPA and SY for 10 days, when compared with IL-6 expression in the BPA group. However, a significant difference in IL-6 expression (P<0.01) was observed between mice exposed simultaneously to SY and BPA and those exposed only to SY.

Furthermore, the pro-inflammatory effect of BPA triggered similar changes in IL-6 and TNF-α transcript levels in mouse hepatic tissue after 10 days of treatment. SY administration for the same interval resulted in a low level of TNF-α expression, significantly lower than the levels obtained for dual BPA and SY exposure (P<0.05). Overall, the TNF-α mRNA levels detected by qPCR in mice treated with both BPA and SY were statistically significantly lower than those in mice treated only with BPA (P<0.05; Fig. 3E).

Protective effects of silymarin against ultrastructural hepatic injuries induced by BPA. Fig. 4 shows that the ultrastructure of hepatocytes was normal in the control group (Fig. 4A) and SY group (Fig. 4G), showing regular organelles and cytoplasmic glycogen deposition. In the BPA-treated group, the majority of the hepatocytes exhibited irregular nuclear shapes, together with damaged rough endoplasmic reticulum (rER), irregular mitochondria and reduced glycogen deposits (Fig. 4B). Some hepatocytes displayed dilated bile canaliculi, voided of microvilli (Fig. 4C). Liver-infiltrating lymphocytes were present in many micrographs (Fig. 4D).

Treatment with 200 mg/kg SY for 10 days significantly reduced the ultrastructural injuries induced by BPA co-administration (Fig. 4E and F). Organelle and cytoplasmic structures were widely protected against the effects of BPA. Abnormal irregular nuclear shapes and dilated bile canaliculi were not visible in the SY+BPA group. Glycogen deposits were increased, while the cytoplasmic distribution of mitochondria and rER was restored. However, proliferation of smooth reticulum vesicles was present (Fig. 4E).

Discussion

BPA is an endocrine-disrupting chemical prevalent in the environment, and previous studies have focused on its effects on reproduction (32,33). Due to limited information concerning the toxic effect on the liver, the present study focused on

| Target | Primer sequence (5' to 3') |
|--------|---------------------------|
| TNF-α  | F: CAGGTTCCTTCAAGGACAAAG R: GCAGAGAGGAGGTTGTACCTTC |
| IL-6   | F: GCAGAGAGGAGGTTGACTTC R: GACAGGTCTGTTGGGAGTGGTATC |
| GAPDH  | F: AGGTCCGTGTTGAACGGATTG R: TGTAGACATGTAATGAGGTC |

TNF, tumor necrosis factor; IL, interleukin; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; F, forward; R, reverse.

inflammation markers were compared with the mRNA levels of the same markers from the control group.

Electron microscopy. Samples were prefixed with 2.7% glutaraldehyde solution in 0.1 M phosphate buffer at 4°C for 1.5 h, washed in 0.15 M phosphate buffer and postfixed in 2% osmic acid solution in 0.15 M phosphate buffer. Dehydration was performed in acetone and the sections were embedded in the epoxy embedding resin Epon 812. Sections of thickness 60 nm were cut with a Leica EM UC7 ultramicrotome (Leica Microsystems GmbH) and analyzed with a Tecnai 12 Biotwin transmission electron microscope.

Statistical analysis. Gene expression data were statistically evaluated using GraphPad Prism 3.03 software (GraphPad Software, Inc., La Jolla, CA, USA), and one-way analysis of variance, followed by a Bonferroni test. P<0.05 was considered to indicate a statistically significant difference. The experiments were performed with n=10 biological replicates and each data set is presented as the average of three replicates (mean ± standard deviation).

Results

Protective effects of silymarin against hepatotoxicity induced by BPA. Histopathological examination and comparison with the control (Fig. 1A), revealed that BPA administration induced necrotic changes of hepatocytes, which were particularly pronounced in the centrilobular area (Fig. 1B). Inflammatory cell infiltration and vascular congestion were also present. In the BPA+SY group, 10 days of 200 mg/kg silymarin administration markedly reduced the hepatocellular changes, as compared with those in the BPA group, and the morphology was not dissimilar to that of the SY group (Fig. 1C). The liver morphology of the SY group (Fig. 1D) was comparable with that of the control group (Fig. 1A).

Protective effects of silymarin against TNF-α and IL-6 hepatic overexpression induced by BPA. Immunohistochemical and gene expression analyses were performed to evaluate the impact of silymarin treatment on the regulation of IL-6 and TNF-α under BPA pro-inflammatory activity. As shown in

Figs. 2 and 3, compared with the control (Figs. 2A and 3A), the administration of BPA caused a significant increase in the number of parenchymal cells immunopositive for IL-6 and TNF-α (Figs. 2B and 3B). No apparent IL-6 or TNF-α expression was detected in non-parenchymal cells. In the BPA+SY group, silymarin treatment decreased the number of cells labeled with both antibodies, compared with the BPA group (Figs. 2C and 3C). No immunopositivity for the group treated with SY alone was detected (Figs. 2D and 3D).

These findings were confirmed by the results of IL-6 and TNF-α RT-qPCR analysis (Figs. 2E and 3E). Evaluation by qPCR demonstrated that exposure to BPA induced high transcript levels of IL-6 in mouse liver tissue (a 1.6-fold increase compared with the control), thus confirming that BPA exerts a hepatotoxic and pro-inflammatory effect (Fig. 2E). Treatment with the natural compound silymarin resulted in very low levels of IL-6 mRNA, comparable with the control. Notably, a statistically significant lower level of IL-6 transcript (P<0.01) was found in livers isolated from mice exposed to a 1:1 ratio of BPA and SY for 10 days, when compared with IL-6 expression in the BPA group. However, a significant difference in IL-6 expression (P<0.01) was observed between mice exposed simultaneously to SY and BPA and those exposed only to SY.

Furthermore, the pro-inflammatory effect of BPA triggered similar changes in IL-6 and TNF-α transcript levels in mouse hepatic tissue after 10 days of treatment. SY administration for the same interval resulted in a low level of TNF-α expression, significantly lower than the levels obtained for dual BPA and SY exposure (P<0.05). Overall, the TNF-α mRNA levels detected by qPCR in mice treated with both BPA and SY were statistically significantly lower than those in mice treated only with BPA (P<0.05; Fig. 3E).

Protective effects of silymarin against ultrastructural hepatic injuries induced by BPA. Fig. 4 shows that the ultrastructure of hepatocytes was normal in the control group (Fig. 4A) and SY group (Fig. 4G), showing regular organelles and cytoplasmic glycogen deposition. In the BPA-treated group, the majority of the hepatocytes exhibited irregular nuclear shapes, together with damaged rough endoplasmic reticulum (rER), irregular mitochondria and reduced glycogen deposits (Fig. 4B). Some hepatocytes displayed dilated bile canaliculi, voided of microvilli (Fig. 4C). Liver-infiltrating lymphocytes were present in many micrographs (Fig. 4D).

Treatment with 200 mg/kg SY for 10 days significantly reduced the ultrastructural injuries induced by BPA co-administration (Fig. 4E and F). Organelle and cytoplasmic structures were widely protected against the effects of BPA. Abnormal irregular nuclear shapes and dilated bile canaliculi were not visible in the SY+BPA group. Glycogen deposits were increased, while the cytoplasmic distribution of mitochondria and rER was restored. However, proliferation of smooth reticulum vesicles was present (Fig. 4E).

Discussion

BPA is an endocrine-disrupting chemical prevalent in the environment, and previous studies have focused on its effects on reproduction (32,33). Due to limited information concerning the toxic effect on the liver, the present study focused on
evaluating the toxic effect of BPA and investigating the potential alleviation of BPA-induced injuries using a natural agent. The present study represents the first report of the ability of silymarin to reduce hepatic lesions and to counteract inflammation caused by BPA administration in animal models. The target of the study was to explore whether a dose of 200 mg/kg silymarin is sufficient to induce a protective effect against structural and ultrastructural injuries induced by BPA and to lower the levels of pro-inflammatory cytokines observed in murine liver tissue following exposure to BPA for 10 days.

Acute hepatotoxicity induces inflammatory effects and hepatocyte apoptosis or necrosis. The necrotic pericentralob-

Figure 1. Effect of SY on histological changes in the livers of BPA-treated mice. (A) Control group, (B) BPA group, (C) BPA+SY group and (D) SY group. The arrow indicates vascular congestion. Hematoxylin and eosin staining. Scale bar, 50 µm. SY, silymarin; BPA, bisphenol A; CV, centrilobular vein.

Figure 2. Suppression of IL-6 by SY in the livers of BPA-treated mice. (A-D) Expression and specific tissue distribution of IL-6 in the experimental groups as revealed by immunohistochemical (diaminobenzidine) staining. (A) In control livers, IL-6 expression was negligible. (B) Strong IL-6 immunopositivity was visible in the parenchymal cells of BPA-treated mice. (C) Reduced IL-6 immunopositivity was observed in mice treated with BPA+SY, compared with the BPA group. (D) Livers of mice receiving SY alone were comparable to the controls. (E) IL-6 gene expression in the experimental groups. Values are presented as mean ± standard deviation (n=10) **P<0.01 vs. the BPA group; ##P<0.01 vs. the SY group. IL, interleukin; SY, silymarin; BPA, bisphenol A.
ular changes, vascular congestion and inflammation observed in histological liver sections are naturally occurring reactions of the system to cell damage ([34]-[36]), as also shown by the histopathological and immunohistochemical results of the present study.

The hepatic inflammatory response is mediated by proinflammatory cytokines, especially TNF-α, the release of which is one of the first events in many types of liver injury, and further modulates the effects of other cytokines, such as IL-6 ([37]). IL-6 is the predominant regulator of the hepatic acute-phase response and modulates liver fibrosis through degrading extracellular matrix proteins by protease inhibition or cytokine binding ([38],[39]). The present study showed that IL-6 and TNF-α are stimulatory, as suggested by higher levels in hepatic tissue and upregulation of their mRNA in mice with BPA-induced liver acute inflammation. Previous data have shown a significant correlation between BPA and inflammatory markers such as IL-6 and TNF-α ([11]). This previous study, involving a homogenous adult male population in southern Italy, revealed that higher BPA plasma levels are associated with higher levels of circulating IL-6 and TNF-α pro-inflammatory cytokines.

Following the administration of 200 mg/kg daily doses of silymarin for 10 days, the present study demonstrated an overall diminished level of IL-6 and TNF-α pro-inflammatory cytokines in mouse liver tissue and attenuation of the inflammatory process. By studying the transcript levels and protein expression of IL-6 and TNF-α pro-inflammatory markers, the present study confirmed at quantitative and qualitative levels a significant reduction in the levels of IL-6 (P<0.01) and TNF-α (P<0.05) in the group exposed to BPA and SY in equal proportions, as compared with the group that received only BPA. This data is in accordance with previous results found in the literature, confirming the anti-inflammatory and hepatoprotective effect of silymarin against toxic substances ([40],[41]). Similarly, a study assessing the toxic effects of sodium nitrate food additive in rat liver ([40]) has identified significant increases in hepatic TNF-α and IL-1β levels in rats exposed to sodium nitrate as compared with their levels in a control group. The co-administration of 80 mg/kg sodium nitrite and 25 mg/kg silymarin for 12 weeks resulted in significant reductions of TNF-α and IL-1β hepatic concentrations, similar to observations in the present study, suggesting that silymarin has a dose-dependent beneficial effect against the impairment of liver function.

The anti-inflammatory effect of silymarin on the liver is supported by additional research. A study using murine knock-out cells ([41]) revealed that nuclear factor-κB, a key transcription factor considered to play a crucial role in the cellular response to signal transduction by TNF-α and IL-6 ([42]), was inhibited through reparative stress signaling. It was concluded that silymarin activates stress and repair responses, which correlates with the ability to suppress inflammation.

The cytotoxic effects of BPA are strongly linked with the production of ROS in liver, kidney and brain tissue, as previ-

Figure 3. Suppression of TNF-α by SY in the livers of BPA-treated mice. (A-D) Expression and specific tissue distribution of TNF-α in the experimental groups as revealed by immunohistochemical (diaminobenzidine) staining. (A) In the control livers, TNF-α expression was negligible. (B) Strong TNF-α immunopositivity was visible in the parenchymal cells of BPA-treated mice. (C) Reduced TNF-α immunopositivity was observed in mice treated with BPA+SY, compared with the BPA group. (D) The livers of mice receiving SY alone were comparable to the controls. (E) TNF-α gene expression in the experimental groups. Values are presented as mean ± standard deviation (n=10). *P<0.05 vs. the BPA group; #P<0.05 vs. the SY group. TNF, tumor necrosis factor; SY, silymarin; BPA, bisphenol A.
The effects of BPA on the liver have been particularly tested, since the liver is the major site exposed to toxicants and oxidative stress, although it possesses an endogenous antioxidant defense system. A study in rats has confirmed that liver damage following exposure to BPA is mainly due to BPA affecting the oxidant/antioxidant balance in the liver (44). Oxidative stress effects are followed by ultrastructural injuries. In the present study, BPA administration caused hepatocyte damage, which resulted in nuclear changes and other organelle impairments. The changes in hepatocyte ultrastructure were probably due to injuries of the membrane structure caused by lipid peroxidation. A parallel study (45) concluded that BPA-induced oxidative stress is similar to the stress produced by hydrogen peroxide. The mechanism proposed for the oxidative-stress increase is based on the lipophilic nature of BPA (46); BPA is likely to interact with the hydrophobic cell plasma membrane, initiating hydroxyl radical formation and the induction of lipid peroxidation (45). Xia et al. (47) demonstrated that BPA induces mitochondria-mediated apoptosis in hepatic cells.

The aforementioned hepatocyte injuries were alleviated by silymarin administration, suggesting that silymarin acts as a free-radical scavenger, while other studies have demonstrated its liver protection effects against paracetamol (23,48), carbon tetrachloride (21,22), anticancer agents (25,26) and lipid peroxidation (27), by enhancement of anti-oxidant status.

Furthermore, the ultrastructural analysis conducted in the present study recorded a significant reduction of glycogen deposits in the BPA group, while a previous study suggested that BPA treatment impairs hepatic glucose oxidation and glycogen content through defective insulin signal transduction (49). Consistent with observations in the present study, significant depletion of glycogen stores has also been reported in the liver tissue of adult male albino rats following 2 weeks of exposure to cisplatin (50). Notably, this previous study and the present one found that silymarin was able to counteract
toxicant activity and restore glycogen to normal levels, thus favoring hepatic glycogenesis. It is generally considered that a harmful toxicant produces enough cellular stress in hepatocytes that glycogenolysis is activated in order to generate increased glucose serum levels (51), which protects cells from effects on hepatocytes (50,53, which are associated with the regulation of carbohydrate metabolism, by restoring serum glucose levels to normal values (50,55).

In conclusion, numerous studies have promoted the exploration of the potential of natural extracts against the negative effects produced by toxicants or pharmacologically harmful compounds in tissues. In this perspective, silymarin has exhibited efficient results in various types of tissues, but particularly in the liver where it can control oxidative, glucidic and lipid metabolism. The current study confirms the hepatoprotective effect of silymarin against exposure to BPA and highlights for the first time its ability to counteract low-grade inflammation caused by BPA administration in animal models. Thus, silymarin holds great promise as an adjuvant therapy for hepatotoxicity, and could be a useful tool to further investigate the mechanism by which metabolic signaling pathways regulate cellular inflammation.

Acknowledgements

This study was supported by a strategic grant (no. POSDRU/159/1.5/S/133939) Project: ‘DoctoralandPost-doctoral programs of excellence for highly qualified human resources training for research in the field of Life sciences, Environment and Earth Science’ cofinanced by the European Social Fund within the Sectorial Operational Program Human Resources Development 2007-2013. This study was also financed by the Institute for Research of the University of Bucharest (ICUB), through ‘Scholarships for Excellence in Research for Young Researchers, 2015 Competition’ Project and START Project: BEST-NetWORK 16_PA07-C1.

References

1. Abdel-Wahab WM: Thymoquinone attenuates toxicity and oxidative stress induced by bisphenol A in liver of male rats. Pak J Biol Sci 17: 1182-1160, 2014.
2. Prichett JJ, Kuester RK and Spies IG: Metabolism of bisphenol A in primary cultured hepatocytes from mice, rats, and humans. Drug Metab Dispos 30: 1180-1185, 2002.
3. Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y and Taketani Y: Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr J 51: 165-169, 2004.
4. Mendiola J, Jørgensen N, Andersson AM, Calafat AM, Ye X, Redmon JB, Drobis EZ, Wang C, Sparks A, Thurston SW, et al: Are environmental levels of bisphenol a associated with reproductive function in fertile men? Environ Health Perspect 118: 1286-1291, 2010.
5. Pupo M, Pisanu A, Lappano R, Santolla MF, De Francesco EM, Abonante S, Rosano C and Maggioni M: Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. Environ Health Perspect 120: 1177-1182, 2012.
6. Lang IA, Galloway TS, Scarlett A, Henley WE, Depledge M, Wallace RB and Melzer D: Association of urinary bisphenol A concentration with medical disorders and laboratory abnormali- ties in adults. JAMA 300: 1303-1310, 2008; Protective effects of silymarin ameliorates the principal functions of the liver, which are associated with the regulation of carbohydrate metabolism, by restoring serum glucose levels to normal values (50,55).

In conclusion, numerous studies have promoted the exploration of the potential of natural extracts against the negative effects produced by toxicants or pharmacologically harmful compounds in tissues. In this perspective, silymarin has exhibited efficient results in various types of tissues, but particularly in the liver where it can control oxidative, glucidic and lipid metabolism. The current study confirms the hepatoprotective effect of silymarin against exposure to BPA and highlights for the first time its ability to counteract low-grade inflammation caused by BPA administration in animal models. Thus, silymarin holds great promise as an adjuvant therapy for hepatotoxicity, and could be a useful tool to further investigate the mechanism by which metabolic signaling pathways regulate cellular inflammation.

Acknowledgements

This study was supported by a strategic grant (no. POSDRU/159/1.5/S/133939) Project: ‘DoctoralandPost-doctoral programs of excellence for highly qualified human resources training for research in the field of Life sciences, Environment and Earth Science’ cofinanced by the European Social Fund within the Sectorial Operational Program Human Resources Development 2007-2013. This study was also financed by the Institute for Research of the University of Bucharest (ICUB), through ‘Scholarships for Excellence in Research for Young Researchers, 2015 Competition’ Project and START Project: BEST-NetWORK 16_PA07-C1.

References

1. Abdel-Wahab WM: Thymoquinone attenuates toxicity and oxidative stress induced by bisphenol A in liver of male rats. Pak J Biol Sci 17: 1182-1160, 2014.
2. Prichett JJ, Kuester RK and Spies IG: Metabolism of bisphenol A in primary cultured hepatocytes from mice, rats, and humans. Drug Metab Dispos 30: 1180-1185, 2002.
3. Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y and Taketani Y: Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr J 51: 165-169, 2004.
4. Mendiola J, Jørgensen N, Andersson AM, Calafat AM, Ye X, Redmon JB, Drobis EZ, Wang C, Sparks A, Thurston SW, et al: Are environmental levels of bisphenol a associated with reproductive function in fertile men? Environ Health Perspect 118: 1286-1291, 2010.
5. Pupo M, Pisanu A, Lappano R, Santolla MF, De Francesco EM, Abonante S, Rosano C and Maggioni M: Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. Environ Health Perspect 120: 1177-1182, 2012.
6. Lang IA, Galloway TS, Scarlett A, Henley WE, Depledge M, Wallace RB and Melzer D: Association of urinary bisphenol A concentration with medical disorders and laboratory abnormali- ties in adults. JAMA 300: 1303-1310, 2008; Protective effects of silymarin ameliorates the principal functions of the liver, which are associated with the regulation of carbohydrate metabolism, by restoring serum glucose levels to normal values (50,55).

In conclusion, numerous studies have promoted the exploration of the potential of natural extracts against the negative effects produced by toxicants or pharmacologically harmful compounds in tissues. In this perspective, silymarin has exhibited efficient results in various types of tissues, but particularly in the liver where it can control oxidative, glucidic and lipid metabolism. The current study confirms the hepatoprotective effect of silymarin against exposure to BPA and highlights for the first time its ability to counteract low-grade inflammation caused by BPA administration in animal models. Thus, silymarin holds great promise as an adjuvant therapy for hepatotoxicity, and could be a useful tool to further investigate the mechanism by which metabolic signaling pathways regulate cellular inflammation.

Acknowledgements

This study was supported by a strategic grant (no. POSDRU/159/1.5/S/133939) Project: ‘DoctoralandPost-doctoral programs of excellence for highly qualified human resources training for research in the field of Life sciences, Environment and Earth Science’ cofinanced by the European Social Fund within the Sectorial Operational Program Human Resources Development 2007-2013. This study was also financed by the Institute for Research of the University of Bucharest (ICUB), through ‘Scholarships for Excellence in Research for Young Researchers, 2015 Competition’ Project and START Project: BEST-NetWORK 16_PA07-C1.

References

1. Abdel-Wahab WM: Thymoquinone attenuates toxicity and oxidative stress induced by bisphenol A in liver of male rats. Pak J Biol Sci 17: 1182-1160, 2014.
2. Prichett JJ, Kuester RK and Spies IG: Metabolism of bisphenol A in primary cultured hepatocytes from mice, rats, and humans. Drug Metab Dispos 30: 1180-1185, 2002.
3. Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y and Taketani Y: Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr J 51: 165-169, 2004.
4. Mendiola J, Jørgensen N, Andersson AM, Calafat AM, Ye X, Redmon JB, Drobis EZ, Wang C, Sparks A, Thurston SW, et al: Are environmental levels of bisphenol a associated with reproductive function in fertile men? Environ Health Perspect 118: 1286-1291, 2010.
5. Pupo M, Pisanu A, Lappano R, Santolla MF, De Francesco EM, Abonante S, Rosano C and Maggioni M: Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. Environ Health Perspect 120: 1177-1182, 2012.
6. Lang IA, Galloway TS, Scarlett A, Henley WE, Depledge M, Wallace RB and Melzer D: Association of urinary bisphenol A concentration with medical disorders and laboratory abnormali-
Vargas-Mendoza N, Madrigal-Santillán E, Morales-González A, Esquivel-Soto J, Esquivel-Chirino C, García-Luna Y González-Rubio M, Gayosso-de-Lucio JA and Morales-González JA: Hepatoprotective effect of silymarin. World J Hepatol 6: 144-149, 2014.

27. Karimi G, Vahabzadeh M, Lari P, Rashedinia M and Moshiri M: 'Silymarin', a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci 14: 308-317, 2011.

28. Tsai JH, Liu JY, Wu TT, Ho PC, Huang CY, Shyu JC, Hsieh YS, Tsai CC and Liu YC: Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats. J Viral Hepat 15: 508-514, 2008.

29. Ahmad I, Shukla S, Kumar A, Singh BK, Kumar V, Chauhan AK, Singh D, Pandey HP and Singh C: Biochemical and molecular mechanisms of N-acetyl cysteine and silymarin-mediated protection against maneb- and paraquat-induced hepatotoxicity in rats. Chem Biol Interact 201: 9-18, 2013.

30. Roelofs MJ, van den Berg M, Bovee TF, Piersma AH and van Duursen MB: Structural bisphenol analogues differentially target steroidogenesis in murine MA-10 Leydig cells as well as the glucocorticoid receptor. Toxicology 329: 10-20, 2015.

31. Weiss MJ: Cytokines in liver, biliary and pancreatic disease. Iran J Basic Med Sci 14: 308‑317, 2011.

32. Thoolen B, Maronpot RR, Koanga Mogtomo ML, Nyska A, Rousseaux C, DeAngelis RA and Lambris JD: Liver inflammation and regeneration: Two distinct biological phenomena or parallel pathophysiological processes? Mol Immunol 43: 45-56, 2006.

33. Thoelen B, Maronpot RR, Harada T, Nyska A, Rousseaux C, Notte T, Malarkey DE, Kaufmann W, Kütterl K, Deschi U, et al: Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system. Toxicol Pathol 38: (7 Suppl) SS-815, 2010.

34. Atsack SS, Kuiate JR, Mouokeu RS, Koanga Mogtomo ML, Tchinda AT, De Dieu TJ, Magnifouet Nana H, Ebelle Etame RM, Biyiti L and Ngono Ngane RA: Toxicological studies of stem bark extract from Schefflera barteri Harms (Araliaceae). BMC Complement Altern Med 15: 44, 2015.

35. Weiss MJ: Cytokines in liver, biliary and pancreatic disease. In: Blumgart's Surgery of the Liver, Pancreas and Biliary Tract. Jarnagin W (ed). 5th edition. Elsevier, Inc., Philadelphia, PA, pp19-27, 2007.